Eli Lilly | LLY - 負債





負債 変化する 日付
AbbVie USD 72.86B 5.36B 2026-03
Abbott USD 34.05B 20.19B 2026-03
ALKERMES USD 1.58B 1.51B 2026-03
Amgen USD 57.32B 2.72B 2026-03
AstraZeneca USD 32.24B 1.68B 2026-06
Baxter International USD 9.69B 93M 2026-03
Biogen USD 8.09B 1.53B 2026-06
Bristol-Myers Squibb USD 46.43B 711M 2026-03
Coherus Biosciences USD 294.92M 1.25M 2025-03
Drreddys Laboratories INR 77.34B 9.61B 2026-03
Eli Lilly USD 43.37B 867M 2026-03
Gilead Sciences USD 22.17B 2.76B 2026-03
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Glaxosmithkline GBP 19.06B 1.31B 2026-03
J&J USD 54.99B 7.05B 2026-03
Medtronic USD 28.07B 1.03B 2025-12
Merck USD 49.12B 222M 2026-03
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 49.01B 2.02B 2026-06
Novartis USD 47B 14.98B 2026-03
Novo Nordisk DKK 118.72B 61.75B 2025-03
Perrigo USD 3.63B 7.7M 2026-03
Pfizer USD 63.73B 231M 2026-03
Phibro Animal Health USD 474.17M 730K 2024-09
Prestige Brands USD 1.05B 33.86M 2026-03
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Roche Holding CHF 33.03B 1.41B 2025-06
Sanofi EUR 23.58B 3.56B 2026-06
Sanofi EUR 20.02B 1.73B 2026-03
United Therapeutics USD 200M 100M 2025-03
Zoetis USD 9.24B 0 2026-03